In the in-vitro[6] study, we firstly demonstrated that KRAS mutant colon cancer cells are more sensitive to oxaliplatin than the same KRAS mutant colon cancer cells in which the expression of mutant KRAS was knocked down by small interfering RNA (siRNA). Here, KRAS is linked to malignant colon neoplasm.